Olysio Sales Reach Higher-Than-Expected $354 Million in First Full Quarter on the Market

Sales of Johnson & Johnson's new hepatitis C drug soared during its first full quarter on the market, in another sign of strong demand—and high prices—for a new generation of treatments for the liver-damaging illness.

The higher-than-expected $354 million in first-quarter sales for J&J's Olysio follows evidence that another new hepatitis C drug, Gilead Sciences Inc.'s Sovaldi, is having one of the best-selling drug launches...